Skip to main content
OpenTrials
Completed

NCT Number: NCT04518813

A Study of a Non-invasive Glucose Measuring Device in Out-patient Settings

This explorative clinical investigation has been launched to collect spectral Raman data paired with validated glucose reference values in persons with diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm

Ulm, 89081, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female subjects minimum 18 years of age
  • Individuals diagnosed with any type of insulin-dependent diabetes mellitus ≥ 1 year
  • Willing to perform up to 12 finger-pricks during each day of out-patient measurements
  • Signed informed consent
  • For women of childbearing potential: Willing and able to practice FDA approved birth control during the duration of the investigation
  • Subject has a 2.4 GHz wireless internet connection at home (standard in normal routers) to be used in the study

Exclusion criteria

  • For female subjects: Pregnancy or breastfeeding
  • Skin phototype VI categorized by Fitzpatrick scale measured on thenar
  • Subjects not able to understand and read local language
  • Cognitive impairment, or in investigator's opinion, subject is not able to follow instructions provided and as specified in the protocol
  • Subject not able to hold hand/arm steady (including tremors and Parkinson's Disease)
  • Extensive skin changes, tattoos or diseases on right thenar (measurement site)
  • Reduced circulation in right hand evaluated by Allen's test
  • Known allergy to medical grade alcohol
  • Hemodialysis
  • Systemic or topical administration of glucocorticoids at the right hand for the past 7 days or during the study period expected
  • Any disorder, which in the investigator's opinion might jeopardize subject's safety or compliance with the protocol
  • Severe diabetes-related complications such as advanced autonomic neuropathy, kidney disease, foot ulcers, legal blindness, or symptomatic cardiovascular disease as evidenced by a history of cardiovascular episode(s)
  • Dependency from the sponsor or the clinical investigator (e.g. co-workers of the sponsor, the study site, and/ or their families)
  • Subjects currently participating in another study
  • Subjects who have participated in the study IDT-1904-RO/RSP-21 or RSP-19.
  • Incapacity for consent

Treatment and study plan

Prototype 0.5

Device

Investigational Medical Device collecting Raman data from tissue

Primary outcomes

  1. Determination of number of calibration days

    Time frame: 2 years

    The number of calibration days needed for reaching a well-performing glucose predictive calibration model will be determined. The clinical performance of the reduced calibration model will be based on the data from the validation part by studying linear regression, Inter Subject Unified Performance value and Consensus Error Grid.

  2. Safety evaluation of the Investigational Medical Device by reporting of adverse events

    Time frame: 2 years

    Safety of the IMD will be evaluated in a descriptive manner by the paucity of adverse events reported during the clinical investigation

Secondary outcomes

  1. Device function

    Time frame: 2 years

    Device function will be evaluated in regard to durability and reliability. This is evaluated by reported device deficiencies during the study in the terms of subject diaries

Sponsors and collaborators

Lead sponsor

RSP Systems A/S

Industry

Registry information

Official study title

An Explorative Study of a Novel Non-invasive Glucose Measuring Device in Out-patient Settings

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Aug 19, 2020
Registry last updated
Nov 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.